Fertility-sparing treatment for cervical mullerian adenosarcoma: A case report and literature review.
10.11817/j.issn.1672-7347.2022.220453
- Author:
Bingxin XIAO
1
;
Ruizhen LI
2
;
Xingping ZHAO
2
;
Xuetao MAO
2
;
Sili HE
3
;
Dabao XU
4
Author Information
1. Department of Gynecology, Third Xiangya Hospital, Central South University, Changsha 410013, China. 992739367@qq.com.
2. Department of Gynecology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
3. Department of Gynecology, Third Xiangya Hospital, Central South University, Changsha 410013, China. 986315943@qq.com.
4. Department of Gynecology, Third Xiangya Hospital, Central South University, Changsha 410013, China. dabaoxu2022@163.com.
- Publication Type:Journal Article
- Keywords:
asexual life young women;
cervical mullerian adenosarcoma;
fertility-sparing treatment;
lifetime follow-up;
uninjured virgin membrane hysteroscopy
- MeSH:
Humans;
Female;
Adolescent
- From:
Journal of Central South University(Medical Sciences)
2022;47(11):1622-1628
- CountryChina
- Language:English
-
Abstract:
Currently, whole uterus and bilateral tubal resection and oophorectomy is the main treatment of cervical mullerian adenosarcoma. However, young patients generally wish to retain reproductive function. The clinical data of a patient with cervical mullerian adenosarcoma, who underwent fertility preservation surgery were collected. A 13-year-old girl with abnormal vaginal bleeding and a 1.0 cm flocculent echogenicity in the lower part of the uterine cavity to the cervical canal and a cervical mass of about 61 mm×37 mm was found in the pelvic MRI. After initial diagnosis of dysfunctional uterine bleeding in adolescence and cervical blood clot, the patient was treated with artificial cycle treatment, but her symptoms did not improve. Then she was transferred to the Third Xiangya Hospital of Central South University for uninjured virgin membrane hysteroscopy and cervical mass electrotomy, but a few pedicles remained after the operation, and the pathology suggested a cervical mullerian adenosarcoma. Because the patient was young and had not yet given birth, she was treated with primary IAP regimen of chemotherapy and subcutaneously injected with gonadotropin-releasing hormone analogue (GNRH-A) once every 28 days (6 times in total) to protect the ovarian function. After the chemotherapy, she was treated with uninjured virgin membrane hysteroscopy and pedicle electrotomy of cervical mullerian adenosarcoma. After the operation, she received chemotherapy with IAP regimen for 5 times. After discharge, she was treated with megestrol 200 mg per day for 3 years. During 5 years of regular follow-up, no abnormality was seen. Cervical mullerian adenosarcoma in non-sexual women is easily misdiagnosed as ovulation dysfunction abnormal uterine bleeding. The necessity of hysteroscopy should be emphasized, and for patients with low-grade early-stage lesions who wish to retain fertility, local resection could be chosen, but attention is paid to lifelong follow-up to exclude long-term recurrence.
